This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valenti, R. Articles by Rivoltini, L. Search for Related Content PubMed PubMed Citation Articles by Valenti, R. Articles by Rivoltini, L.

Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-ß–Mediated Suppressive Activity on T Lymphocytes

¹ Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori; ² Fondazione D'Amico, Milan, Italy; ³ Microscopy and Image Analysis Consortium; ⁴ Dipartimento di Neuroscienze e Tecnologie Biomediche, Università Milano-Bicocca, Monza, Italy; and ⁵ Department of Drug Research and Evaluation, Section of Pharmacogenetic, Drug Resistance and Experimental Therapeutics, Istituto Superiore di Sanità, Rome, Italy

Requests for reprints: Licia Rivoltini, Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-2-2390-3245; Fax: 39-2-2390-2154; E-mail: rivoltini{at}istitutotumori.mi.it.

Human tumors constitutively release endosome-derived microvesicles, transporting a broad array of biologically active molecules with potential modulatory effects on different immune cells. Here, we report the first evidence that tumor-released microvesicles alter myeloid cell function by impairing monocyte differentiation into dendritic cells and promoting the generation of a myeloid immunosuppressive cell subset. CD14⁺ monocytes isolated from healthy donors and differentiated with interleukin (IL)-4 and granulocyte macrophage colony-stimulating factor in the presence of tumor-derived microvesicles turned into HLA-DR^–/low cells, retaining CD14 expression and failing to up-regulate costimulatory molecules, such as CD80 and CD86. These phenotypic changes were paralleled by a significant release of different cytokines, including IL-6, tumor necrosis factor-, and transforming growth factor-ß (TGF-ß), and a dose-dependent suppressive activity on activated T-cell–proliferation and cytolytic functions, which could be reversed by anti-TGF-ß–neutralizing antibodies. Microvesicles isolated from plasma of advanced melanoma patients, but not from healthy donors, mediated comparable effects on CD14⁺ monocytes, skewing their differentiation toward CD14⁺HLA-DR^–/low cells with TGF-ß–mediated suppressive activity on T-cell–functions. Interestingly, a subset of TGF-ß–secreting CD14⁺HLA-DR^– cells mediating suppressive activity on T lymphocytes was found to be significantly expanded in peripheral blood of melanoma patients compared with healthy donors. These data suggest the development in cancer patients of an immunosuppressive circuit by which tumors promote the generation of suppressive myeloid cells through the release of circulating microvesicles and without the need for cell-to-cell contact. Therapeutic interventions on the crucial steps of this pathway may contribute to restore tumor/immune system interactions favoring T-cell–mediated control of tumor growth in cancer patients. (Cancer Res 2006; 66(18): 9290-8)

This article has been cited by other articles:

				E. U. Wieckowski, C. Visus, M. Szajnik, M. J. Szczepanski, W. J. Storkus, and T. L. Whiteside Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes J. Immunol., September 15, 2009; 183(6): 3720 - 3730. [Abstract] [Full Text] [PDF]

				M. W. Graner, O. Alzate, A. M. Dechkovskaia, J. D. Keene, J. H. Sampson, D. A. Mitchell, and D. D. Bigner Proteomic and immunologic analyses of brain tumor exosomes FASEB J, May 1, 2009; 23(5): 1541 - 1557. [Abstract] [Full Text] [PDF]

				F. Pages, J. Galon, and W. H. Fridman The essential role of the in situ immune reaction in human colorectal cancer J. Leukoc. Biol., October 1, 2008; 84(4): 981 - 987. [Abstract] [Full Text] [PDF]

				H. van Cruijsen, A. A.M. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B.A.G. Haanen, A. J.M. van den Eertwegh, E. Boven, et al. Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Clin. Cancer Res., September 15, 2008; 14(18): 5884 - 5892. [Abstract] [Full Text] [PDF]

				I. S. Zeelenberg, M. Ostrowski, S. Krumeich, A. Bobrie, C. Jancic, A. Boissonnas, A. Delcayre, J.-B. Le Pecq, B. Combadiere, S. Amigorena, et al. Targeting Tumor Antigens to Secreted Membrane Vesicles In vivo Induces Efficient Antitumor Immune Responses Cancer Res., February 15, 2008; 68(4): 1228 - 1235. [Abstract] [Full Text] [PDF]

				C. Eken, O. Gasser, G. Zenhaeusern, I. Oehri, C. Hess, and J. A. Schifferli Polymorphonuclear Neutrophil-Derived Ectosomes Interfere with the Maturation of Monocyte-Derived Dendritic Cells J. Immunol., January 15, 2008; 180(2): 817 - 824. [Abstract] [Full Text] [PDF]

				G. Ferretti, A. Felici, F. Cognetti, and M. Mandala Transforming Growth Factor-{beta} Signaling and Regulatory T Cells J. Clin. Oncol., October 10, 2007; 25(29): 4695 - 4696. [Full Text] [PDF]

				P. Filipazzi, C. Castelli, V. Roberta, V. Huber, M. Iero, L. Pilla, L. Rivoltini, and G. Parmiani In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4696 - 4697. [Full Text] [PDF]

				P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor-Based Antitumor Vaccine J. Clin. Oncol., June 20, 2007; 25(18): 2546 - 2553. [Abstract] [Full Text] [PDF]

				C. Liu, S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H.-G. Zhang Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host Blood, May 15, 2007; 109(10): 4336 - 4342. [Abstract] [Full Text] [PDF]

				R. Valenti, V. Huber, M. Iero, P. Filipazzi, G. Parmiani, and L. Rivoltini Tumor-Released Microvesicles as Vehicles of Immunosuppression Cancer Res., April 1, 2007; 67(7): 2912 - 2915. [Abstract] [Full Text] [PDF]